2017-2018 Report on Fees

Download the alternative format
(Format PDF, 413 Ko, 46 page)

Erratum

Under heading "Financial totals for all fee categories", the "2017-18 Total revenue (dollars)" should read 125,104,350 (currently states 123,425,415).

Minister's message

As the Minister of Health, I am pleased to present the Health Canada 2017 to 2018 Report on Fees, which sets out detailed information on fees in the Department. These fees support the sustainability of Health Canada's regulatory programs and activities, which protect the health and safety of Canadians. On June 22, 2017, the Service Fees Act received Royal Assent, thereby repealing the User Fees Act. The Service Fees Act introduces a modern legislative framework that enables cost-effective delivery of services and, through enhanced reporting to Parliament, improved transparency and oversight. The Act provides for:

This 2017-18 Fees Report is the first report to be prepared by Health Canada under the Service Fees Act. The report includes new information, such as a detailed listing of all fees along with future-year fee amounts. Additional fee information will be included starting next fiscal year, once Health Canada fully transitions to the Service Fees Act regime. Health Canada's fee portfolio changed in the following ways, as reflected in the 2017-18 report:

I welcome the increased transparency and oversight that the Service Fees Act's reporting regime embodies, and I am fully committed to transitioning my department to this modern framework. I look forward to continuing to advance my key mandate priorities through collaboration and evidence-based decision-making that will maintain and improve the health and safety of all Canadians.

The Honourable Ginette Petitpas Taylor, P.C., M.P.
Minister of Health

General fees information

The tables that follow provide information on each category of fees, including:

In addition to the information presented by fee category, there is a summary of the financial information for all fees as well as a listing of fees under the department's authority. This listing includes the existing dollar amounts and the adjusted dollar fee amount for a future year.

General and financial information by fee category

General information
Fee category: Fees for Right to Sell Drugs
Fee-setting authority: Financial Administration Act
Year introduced: 1995
Year last amended: 2011
Service standard: 120 calendar days to update the Drug Product Database following notification
Performance results: 100% within 120 calendar days
Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
12,015,179 12,200,583 63,830,126 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Fee for Right to Sell a Licensed Class II, III or IV Medical Device

Fee-setting authority: Financial Administration Act

Year introduced: 1999

Year last amended: 2011

Service standard: 20 calendar days from deadline for receipt of annual notification to update the Medical Devices License Listing (MDALL) database

Performance results: 99.1% within 20 calendar days

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
8,412,791 8,955,877 15,713,214 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Fees for the Examination of a Drug Submission (Pharmaceuticals and Biologic Products)

Fee-setting authority: Financial Administration Act

Year introduced: 1995

Year last amended: 2011

Service Standards - Pharmaceuticals
Fee Name Submission Type Service Standard - Review 1 (average time in calendar days)
New Active Substance New Drug Submission 300
Clinical/ Chemistry & Manufacturing New Drug Submission 300
Supplement to a New Drug Submission 300
Clinical Only New Drug Submission 300
Supplement to a New Drug Submission 300
Drug Identification Number Application - Pharmaceutical 210
Comparative Studies / Chemistry & Manufacturing Abbreviated New Drug Submission 180
New Drug Submission 180
Supplement to an Abbreviated New Drug Submission 180
Supplement to a New Drug Submission 180
Drug Identification Number Application - Pharmaceutical 210
Chemistry & Manufacturing Abbreviated New Drug Submission 180
New Drug Submission 180
Supplement to an Abbreviated New Drug Submission 180
Supplement to a New Drug Submission 180
Drug Identification Number Application - Pharmaceutical 210
  Published Data Supplement to a New Drug Submission 300
Supplement to an Abbreviated New Drug Submission 300
Drug Identification Number Application - Pharmaceutical 210
Switch from Prescription to Over the Counter New Drug Submission 180
Supplement to a New Drug Submission 180
Disinfectant New Drug Submission 300
Supplement to a New Drug Submission 300
Drug Identification Number Application – Disinfectant 210 210
Drug Identification Number Application – Disinfectant 180 180
Labelling Only New Drug Submission 60
Supplement to a New Drug Submission 60
Abbreviated New Drug Submission 60
Supplement to an Abbreviated New Drug Submission 60
Drug Identification Number Application - Pharmaceutical 180
Label Standard Drug Identification Number Application - Pharmaceutical 45
Drug Identification Number Application – Disinfectant 45
Drug Identification Number Application – Category IV 45
Administrative Abbreviated New Drug Submission 45
New Drug Submission 45
Supplement to a New Drug Submission 45
Supplement to an Abbreviated New Drug Submission 45
Drug Identification Number Application - Pharmaceutical 45
Drug Identification Number Application – Disinfectant 45
Drug Identification Number Application – Category IV 45
Service Standards - Biologics
Fee Name Submission Type Service Standard - Review 1 (average time in calendar days)
New Active Substance New Drug Submission 300
Clinical/ Chemistry & Manufacturing New Drug Submission 300
Supplement to a New Drug Submission 300
Drug Identification Number Application - Biologics 210
Clinical Only New Drug Submission 300
Supplement to a New Drug Submission 300
Comparative Studies/ Chemistry & Manufacturing Abbreviated New Drug Submission 180
Supplement to a New Drug Submission 180
Drug Identification Number Application - Biologics 210
Chemistry & Manufacturing Abbreviated New Drug Submission 180
Supplement to an Abbreviated New Drug Submission 180
Supplement to a New Drug Submission 180
Drug Identification Number Application - Biologics 210
Labelling Only New Drug Submission 60
Supplement to a New Drug Submission 60
Drug Identification Number Application - Biologics 180
Published Data Supplement to a New Drug Submission 300
Administrative New Drug Submission 45
Drug Identification Number Application - Biologics 42
Performance Results - Pharmaceuticals
Fee Name Submission Type Results - Review 1 (average time in calendar days)
New Active Substance New Drug Submission 269
Clinical/ Chemistry & Manufacturing New Drug Submission 300
Supplement to a New Drug Submission 270
Clinical Only New Drug Submission N/A
Supplement to a New Drug Submission 269
Drug Identification Number Application - Pharmaceutical 204
Comparative Studies / Chemistry & Manufacturing Abbreviated New Drug Submission 164
New Drug Submission 180
Supplement to an Abbreviated New Drug Submission 171
Supplement to a New Drug Submission 155
Drug Identification Number Application - Pharmaceutical 200
Chemistry & Manufacturing Abbreviated New Drug Submission 167
New Drug Submission N/A
Supplement to an Abbreviated New Drug Submission 149
Supplement to a New Drug Submission 167
Drug Identification Number Application - Pharmaceutical 191
  Published Data Supplement to a New Drug Submission 269
Supplement to an Abbreviated New Drug Submission 276
Drug Identification Number Application - Pharmaceutical 206
Switch from Prescription to Over the Counter New Drug Submission N/A
Supplement to a New Drug Submission N/A
Disinfectant New Drug Submission 299
Supplement to a New Drug Submission N/A
Drug Identification Number Application – Disinfectant 210 208
Drug Identification Number Application – Disinfectant 180 171
Labelling Only New Drug Submission 52
Supplement to a New Drug Submission 55
Abbreviated New Drug Submission 41
Supplement to an Abbreviated New Drug Submission 46
Drug Identification Number Application - Pharmaceutical 158
Label Standard Drug Identification Number Application - Pharmaceutical 39
Drug Identification Number Application – Disinfectant 38
Drug Identification Number Application – Category IV 38
Administrative Abbreviated New Drug Submission 26
New Drug Submission 33
Supplement to a New Drug Submission 27
Supplement to an Abbreviated New Drug Submission 31
Drug Identification Number Application - Pharmaceutical 29
Drug Identification Number Application – Disinfectant 38
Drug Identification Number Application – Category IV 34
Performance Results - Biologics
Fee Name Submission Type Results - Review 1 (average time in calendar days)
New Active Substance New Drug Submission 260
Clinical/ Chemistry & Manufacturing New Drug Submission 292
Supplement to a New Drug Submission 293
Drug Identification Number Application - Biologics N/A
Clinical Only New Drug Submission N/A
Supplement to a New Drug Submission 277
Comparative Studies/ Chemistry & Manufacturing Abbreviated New Drug Submission 177
Supplement to a New Drug Submission 179
Drug Identification Number Application - Biologics 177
Chemistry & Manufacturing Abbreviated New Drug Submission 177
Supplement to an Abbreviated New Drug Submission N/A
Supplement to a New Drug Submission 136
Drug Identification Number Application - Biologics 176
Labelling Only New Drug Submission 60
Supplement to a New Drug Submission 57
Drug Identification Number Application - Bioligics 164
Published Data Supplement to a New Drug Submission 270
Administrative New Drug Submission 28
Drug Identification Number Application - Biologics 42

Other information:

Review 1= Drug Submission Reviews

N/A: At time of reporting either no submissions of that type were received or no reviews of that submission type were completed, therefore no performance information available.

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
43,609,604 47,998,937 102,956,423 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Certificate of Supplementary Protection Application Fees

Fee-setting authority: Patent Act

Year introduced: 2017

Year last amended: N/A

Service standard: 60 calendar days

Performance results: 43 calendar days

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
Cost Footnote *
2017–18
RemissionsFootnote
N/A 117,143 155,181 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Fees for the Examination of Medical Device License Applications

Fee-setting authority:  Financial Administration Act

Year introduced: 1998

Year last amended: 2011

Service standards:

Fee Name Service Standard - Review 1 (average time in calendar days)
Class II Licence Application 15
Class III Licence Application 60
Class III Licence Application (Near Patient In Vitro Diagnostic Devices) 60
Class III Changes in Manufacturing 60
Class III Significant Changes 60
Class IV Licence Application 75
Class IV Licence Application (Devices that contain Human-Animal Tissue) 75
Class IV Licence Application (Near Patient In Vitro Diagnostic Devices) 75
Class IV Changes in Manufacturing 75
Class IV Significant Changes 75

Performance results

Fee Name Results - Review 1 (average time in calendar days)
Class II Licence Application 12
Class III Licence Application 52
Class III Licence Application (Near Patient In Vitro Diagnostic Devices) 56
Class III Changes in Manufacturing 54
Class III Significant Changes 51
Class IV Licence Application 68
Class IV Licence Application (Devices that contain Human-Animal Tissue) 64
Class IV Licence Application (Near Patient In Vitro Diagnostic Devices) N/A
Class IV Changes in Manufacturing 51
Class IV Significant Changes 59

Other information:
N/A: At time of reporting either no submissions of that type were received or no reviews of that submission type were completed, therefore no performance information available.

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
6,261,776 6,116,671 20,979,592 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Veterinary Drug Evaluation Fee

Fee-setting authority: Financial Administration Act

Year introduced: 1996

Year last amended: N/A

Service standards:

Fee Name Service Standard - Review 1 (average time in calendar days)
New Drug Submission 300
Abbreviated New Drug Submission 300
Supplement to a New Drug Submission 240
Supplement to an Abbreviated New Drug Submission 240
Administrative 90
Drug Identification Number  (including changes) 120
Notifiable Change 90
Experimental Studies Certificate 60
Labels (No longer reviewed) 45
Emergency Drug Release 2

Performance Results:

Fee Name Results - Review 1 (average time in calendar days)
New Drug Submission 310
Abbreviated New Drug Submission 287
Supplement to a New Drug Submission 225
Supplement to an Abbreviated New Drug Submission 204
Administrative 11
Drug Identification Number  (including changes) 110
Notifiable Change 71
Experimental Studies Certificate 57
Labels (No longer reviewed) N/A
Emergency Drug Release 2

Other information:

Review 1= Drug Submission Reviews

N/A: No longer reviewed.

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
833,874 1,114,183 6,110,102 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Drug Establishment Licensing Fees

Fee-setting authority: Financial Administration Act

Year introduced: 1998

Year last amended: 2011

Service standard: 250 calendar days to issue / renew license

Performance results: Average of 122 calendar days

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
16,766,144 16,593,274 22,472,562 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Medical Device Establishment Licensing Fees

Fee-setting authority: Financial Administration Act

Year introduced: 2000

Year last amended: 2011

Service standard: 120 calendar days to issue / renew license

Performance results: Average of 22 calendar days

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
10,655,054 10,134,538 9,336,613 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Fees to be Paid for the Examination of an Application in Respect of a Pest Control Product

Fee-setting authority: Pest Control Products Act

Year introduced: 1997

Year last amended: 2017

Service standard: The performance standard is 90% of applications are to be processed within the applicable review timelines.

Description Service Standards
Category A New active ingredients or integrated system products, their related end-use products, and manufacturing-use products; Major new use of registered pest control products (defined as the addition of a new use-site category to the use pattern for a specific registered active ingredient); Specification of import Maximum Residue Limits (MRLs) for an unregistered active ingredient. 285 to 655 days
Category B New pest control products containing registered active ingredients; Amendment to existing pest control products (for example, product chemistry, labelling); Emergency registration' the addition of import MRLs for previously assessed active ingredients. 158 to 425 days
Category C Product registrations and amendments with no data requirements. These applications involve minor label or formulation reviews, such as product registration based on registered precedent products. 180 to 240 days
Category D Submissions within particular programs including: Import for Manufacture and Export Program (IMEP), Own Use Import (OUI), Grower Requested Own Use (GROU) Equivalency and import permits, Master Copies, Private Labels, Registration Renewal, and Discontinuations. 10 to 244 days
Category E Research authorizations for new active ingredients and new use(s) of registered active ingredients; Research notification for research carried out in Canada. 30 to 159 days
Category F Registration and amendments to registered pest control products via notification 45 days
Category L Submissions to register or amend products including new sources of technical grade active ingredient, manufacturing concentrates and end use products where the applicant wishes to use or rely upon data provided by another registrant; Requests to extend the exclusive use protection period based upon minor uses. 45 to 425 days

Performance results

Description Results
Category A New active ingredients or integrated system products, their related end-use products, and manufacturing-use products; Major new use of registered pest control products (defined as the addition of a new use-site category to the use pattern for a specific registered active ingredient); Specification of import MRLs for an unregistered active ingredient. 88% within 285 to 655 days
Category B New pest control products containing registered active ingredients; Amendment to existing pest control products (for example, product chemistry, labelling); Emergency registration' the addition of import MRLs for previously assessed active ingredients. 92% within 158 to 425 days
Category C Product registrations and amendments with no data requirements. These applications involve minor label or formulation reviews, such as product registration based on registered precedent products. 97% within 180 to 240 days
Category D Submissions within particular programs including: Import for Manufacture and Export Program (IMEP), Own Use Import (OUI), Grower Requested Own Use (GROU) Equivalency and import permits, Master Copies, Private Labels, Registration Renewal, and Discontinuations. 99% within 10 to 244 days
Category E Research authorizations for new active ingredients and new use(s) of registered active ingredients; Research notification for research carried out in Canada. 31% within 30 to 159 days
Category F Registration and amendments to registered pest control products via notification 92% within 45 days
Category L Submissions to register or amend products including new sources of technical grade active ingredient, manufacturing concentrates and end use products where the applicant wishes to use or rely upon data provided by another registrant; Requests to extend the exclusive use protection period based upon minor uses. 93% within 45 to 425 days

Other information:

Service standards are defined in Regulatory Directive DIR2017-01 Management of Submissions Policy (MOSP), March 8, 2017

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
2,590,800 5,218,518 33,159,373 N/A
Footnote *

Starting in 2017 the Pesticides Program revised the methodology to calculate costs for reporting. In previous years the Pesticides Program used direct expenditures, for 2017/18 the Pesticide Program has utilized the activity time tracking system with a full program costing methodology, consistent with other Programs in Health Canada

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: Annual Charge (for a registered Pest Control Product)

Fee-setting authority: Pest Control Products Act

Year introduced: 1997

Year last amended: 2017

Service standard: 100% of all invoices were issued by April 30, 2017

Performance results: 100%

Other information:

Annual Charge fees are identified in the Pest Control Products Fees and Charges Regulations (PCPFCR – April 1, 2017), in Part 2 –Annual Charge

Under the Service Fees Act, this fee is subject to Section 17(1) Annual Adjustment - Consumer Price Index, which will occur on April 1 of each year, commencing April 1, 2019.

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
5,304,300 8,174,445 24,084,509 N/A
Footnote *

Starting in 2017 the Pesticides Program revised the methodology to calculate costs for reporting. In previous years the Pesticides Program used direct expenditures, for 2017/18 the Pesticide Program has utilized the activity time tracking system with a full program costing methodology, consistent with other Programs in Health Canada.

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category:  Fees charged for filing a claim for exemption under the Hazardous Materials Information Review Act

Fee-setting authority:

Year introduced: 1988

Year last amended: 2002

Service standard: The Workplace Hazardous Materials Bureau commits to a service delivery standard of 7 calendar days from the date of the receipt of a complete application, for the issuance of a registry number on an application for a claim for exemption for Confidential Business Information (CBI).

Performance results: In 2017-18, the Bureau processed 99% of claims for exemption applications within its service standard.  Annual service performance is measured over the course of the fiscal year (e.g., April 1 - March 31).

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
Cost Footnote *
2017–18
RemissionsFootnote
1,283,546 1,056,287 2,673,267 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard.   Under the Service Fees Act departments are required to develop policies that determine when fees will be remitted to fee payers should service standards not be met. The requirement for departments to remit is anticipated to come into effect on April 1, 2020.

Return to footnote referrer

General information

Fee category: National Dosimetry Services Products, Services and Fees Structure

Fee-setting authority: Ministerial Authority to enter into Contract

Year introduced: 2004

Year last amended: 2017

Service standards:

Provide timely, responsive and reliable dosimetry services:

  1. Exposures reported within 45 calendar days of receipt – Canadian Nuclear Safety Commission (CNSC) regulatory standard;
  2. Dosimeters shipped 10-13 working days prior to exchange date with clients;
  3. Dose results for whole body and extremity services reported within internal service standards of 20-30 business days, depending on the dosimetry service;
  4. Client account information updated within two business days;
  5. Client voice mails responded to within one business day; and,
  6. Client emails responded to within two business days.

Performance results:

National Dosimetry Service (NDS) provided timely, accurate and reliable customer service to workers:

  1. NDS processed and reported 611,042 dosimeter readings to client groups attaining 100% compliance with the 45 day regulatory (CNSC) standard;
  2. NDS shipped out 88% of dosimeters 10-13 working days prior to exchange date;
  3. NDS processed and reported 611,042 readings with 99% reported within the 20-30 business day internal standard, depending on the dosimetry service;
  4. NDS processed 28,371 changes to client group requests (via Name Lists) with 94% completed within two business days;
  5. NDS responded to 1,585 Client Services voice mail call backs with 91.1% being addressed within one business day; and,
  6. NDS responded to 4,615 emails with 90.1% addressed within two business days.

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
5,810,715 6,163,812 6,140,049 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard. Some fees are exempt, such as those fixed by contract or under the Access to Information Act.

Return to footnote referrer

General information

Fee category: Drug Master File Fees

Fee-setting authority: Ministerial Authority to enter into Contract

Year introduced: 1996

Year last amended: 2017

Service standard: 30 calendar days

Performance results: 98%

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
RemissionsFootnote
773,663 993,181 1,469,899 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard. Some fees are exempt, such as those fixed by contract or under the Access to Information Act.

Return to footnote referrer

General information

Fee category: Certificate of Pharmaceutical Product Fees

Fee-setting authority: Ministerial Authority to enter into Contract

Year introduced: 1996

Year last amended: N/A

Service standard: 10 calendar days to issue certificate

Performance results: Average of eight calendar days

Other information: N/A

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
Cost Footnote *
2017–18
RemissionsFootnote
274,449 258,731 287,637 N/A
Footnote *

The amount includes direct and indirect costs, where such costs are identifiable and material

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard. Some fees are exempt, such as those fixed by contract or under the Access to Information Act.

Return to footnote referrer

General information

Fee category: Fees for processing requests filed under the Access to Information Act

Fee-setting authority: Access to Information Act

Year introduced: 1988

Year last amended: 1992

Service standard: A response is provided within 30 days following receipt of a request; the response time may be extended under section 9 of the Access to Information Act.

Performance results: Health Canada achieved a compliance rate* of 59.5% for fiscal 2017-18. Public Health Agency of Canada achieved a compliance rate* of 77.2% for fiscal 2017-18.

* Includes cases where a Notice of Extension is sent to the requester within 30 days of receipt of the request.

Other information:

The Act authorizes fees for certain aspects of processing formal requests and the fee structure is prescribed in the Access to Information (ATI) Regulations. However, Treasury Board Secretariat in May 2016 issued the Interim Directive on the Administration of the Access to Information Act which imposed a requirement to waive all fees chargeable other than the $5 application fee, regardless of the size and scope of the request or burden on the Department to process. Based on requests received in 2017-18, Health Canada collected $7,655 in application fees, and Public Health Agency of Canada collected $515 in application fees. Health Canada waived $2,788 in fees while Public Health Agency of Canada waived $313 in fees.

Financial information (dollars)

2016–17
Revenue
2017–18
Revenue
2017–18
CostFootnote *
2017–18
Remissions Footnote
6,928 8,170 10,960,057 N/A
Footnote *

* The amount includes direct and indirect costs. Due to the Shared Services Partnership whereby Health Canada provides Access to Information (ATI) services on behalf of Public Health Agency of Canada, the Fiscal Year 2017-18 total costs detailed between the 2 departments are as follows:

  • Health Canada Access to Information (ATI) - $10,304,134
  • Public Health Agency of Canada Access to Information ( ATI) - $655,923

Return to footnote * referrer

Footnote †

A remission is a partial or full return of a fee paid as a result of a missed performance standard. Some fees are exempt, such as those fixed by contract or under the Access to Information Act.

Return to footnote referrer

Financial totals for all fee categories

Total revenues, cost and remissions (dollars)

2016–17
Total revenue
2017–18
Total revenue
2017–18
Total cost
2017–18
Total remissions
114,598,823 125,104,350 320,328,604 N/A

Note: the totals are the sums of the revenues, costs and remissions reported for all fee categories in the "Financial information" tables.

The 2016-17 total revenue as published in the 2016-17 Departmental Results Report did not include Fees set by Ministerial Authority to enter into Contract ($6,858,828).

Fees under the department's authority

Fee amounts for 2017–18 and 2019–20 and for a future fiscal year, as applicable (dollars).

The 2019-20 adjusted fee amounts reflect either:

Future fee amount and fiscal year would be the new amount of the fee, in a future fiscal year other than 2019 to 2020, adjusted by a predetermined rate in accordance with the authority in legislation or regulation. This is not applicable for any Health Canada fees.

Note: Health Canada held official consultations on the Fee Proposal for Drugs and Medical Devices, which aimed to update regulatory fees related to human drugs, medical devices and veterinary drugs to reflect the current costs of regulatory activities. Work is ongoing to finalize these updates and as such, fees contained within this report do not reflect proposed changes.

Name of fee 2017-18 Fee Amount 2019-20 Adjusted fee amount Future fee amount and fiscal year
RIGHT TO SELL DRUGS FEE Footnote 1
Human drugs 1,152 1,200 Not applicable
Vet Drugs 250 255.50 Not applicable
FEE FOR RIGHT TO SELL A LICENSED MEDICAL DEVICE Footnote 1
Medical Device Right to Sell (if annual gross revenue medical device sales is less than $20,000) 61 65 Not applicable
Medical Device Right to Sell (in any other cases) 375 391 Not applicable
DRUG SUBMISSION EVALUATION FEES (PHARMACEUTICALS AND BIOLOGIC PRODUCTS) Footnote 1
New active substance 341,770 355,579 Not applicable
Clinical or non-clinical data and chemistry and manufacturing data 173,106 180,101 Not applicable
Clinical or non-clinical data only 80,794 84,059 Not applicable
Comparative studies 48,834 50,808 Not applicable
Chemistry and manufacturing data only 23,089 24,023 Not applicable
Published data only 19,147 19,921 Not applicable
Switch from prescription to non-prescription status 46,491 48,370 Not applicable
Labelling only 3,111 3,238 Not applicable
Administrative Submission 324 338 Not applicable
Disinfectants 4,305 4,480 Not applicable
Drug identification number application – labelling standards 1,726 1,797 Not applicable
Remission Processing Fee 566 590 Not applicable
CERTIFICATE OF SUPPLEMENTARY PROTECTION APPLICATION FEES
Certificate of Supplementary Protection 9,011 9,376 Not applicable
MEDICAL DEVICE LICENSE APPLICATION FEES Footnote 1
Class II - Licence Application 397 414 Not applicable
Class III - Licence Application 5,691 5,922 Not applicable
Class III - Licence Application (Near patient In Vitro Diagnostic Devices) 9,687 10,079 Not applicable
Class III – Changes in Manufacturing 1,433 1,492 Not applicable
Class III – Significant Changes 5,330 5,546 Not applicable
Class IV - Licence Application 13,235 13,770 Not applicable
Class IV - Licence Application (Devices that contain Human- Animal Tissue) 12,347 12,846 Not applicable
Class IV - Licence Application (Near patient In Vitro Diagnostic Device) 22,560 23,473 Not applicable
Class IV - Changes in Manufacturing 1,433 1,492 Not applicable
Class IV - Significant Changes 6,073 6,319 Not applicable
Remission Processing Fee 61 65 Not applicable
VETERINARY DRUG EVALUATION FEES Footnote 1
New Drug Submission:
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species.) 15,980 16,331.56 Not applicable
Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species. 9,680 9,892.96 Not applicable
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species. 23,240 23,751.28 Not applicable
Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species. 31,470 32,162.34 Not applicable
Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration 2,900 2,963.80 Not applicable
Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength. 480 490.56 Not applicable
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. 21,790 22,269.38 Not applicable
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. 29,050 29,689.10 Not applicable
For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration. 2,900 2,963.80 Not applicable
For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species. 14,520 14,839.44 Not applicable
Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug. 4,840 4,946.48 Not applicable
Chemistry and manufacturing data to support one strength of a single dosage form. 4,840 4,946.48 Not applicable
Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the above item. 2,420 2,473.24 Not applicable
Documentation to support a change of manufacturer. 250 255.50 Not applicable
Supplement to a New Drug Submission: 
Efficacy data to support an additional indication in one animal species. 12,590 12,866.98 Not applicable
Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species. 9,680 9,892.96 Not applicable
Efficacy and safety data (in the intended species) to support an indication in another animal species. 15,980 16,331.56 Not applicable
Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species. 23,240 23,751.28 Not applicable
Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species. 31,470 32,162.34 Not applicable
Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species. 7,740 7,910.28 Not applicable
Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration. 2,900 2,963.80 Not applicable
Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength. 480 490.56 Not applicable
For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species. 2,900 2,963.80 Not applicable
For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species. 14,520 14,839.44 Not applicable
For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period. 7,260 7,419.72 Not applicable
For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required. 5,810 5,937.82 Not applicable
Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process. 4,840 4,946.48 Not applicable
Chemistry and manufacturing data to support a change in formulation or dosage form. 2,420 2,473.24 Not applicable
Chemistry and manufacturing data to support a change in packaging or in the sterilization process. 1,930 1,972.46 Not applicable
Chemistry and manufacturing data to support an extension of the expiry dating. 1,450 1,481.90 Not applicable
Chemistry and manufacturing data to support the concurrent use of two drugs. 1,450 1,481.90 Not applicable
Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms. 480 490.56 Not applicable
Documentation to support a change to the name of a manufacturer or the brand name of a drug. 250 255.50 Not applicable
Abbreviated New Drug Submission and Supplement to an Abbreviated New Drug Submission:
Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form. 2,900 2,963.80 Not applicable
For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product. 2,900 2,963.80 Not applicable
Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug. 4,840 4,946.48 Not applicable
Chemistry and manufacturing data to support a single dosage form. 4,840 4,946.48 Not applicable
Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission. 250 255.50 Not applicable
Drug Identification Number Application:
Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required. 720 735.84 Not applicable
Published references or other data. 500 511.00 Not applicable
Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug. 250 255.50 Not applicable
Preclinical New Drug Submission:
Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species. 4,840 4,946.48 Not applicable
Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated. 3,870 3,955.14 Not applicable
For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. 14,520 14,839.44 Not applicable
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. 21,790 22,269.38 Not applicable
For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. 29,050 29,689.10 Not applicable
For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species. 7,260 7,419.72 Not applicable
Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient. 4,840 4,946.48 Not applicable
Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient. 2,420 2,473.24 Not applicable
Notifiable Change or Protocol Review:
Information and material to support an application for Notifiable Change 1,300 1,300 Not applicable
Request for review of scientific  information outside of a regular drug submission (i.e. review of a proposed trial protocol) 1,300 1,300 Not applicable
Experimental Studies Certificate:
Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal. 960 981.12 Not applicable
Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal. 480 490.56 Not applicable
Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal. 2,900 2,963.80 Not applicable
Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal. 480 490.56 Not applicable
Emergency Drug Sale:
Information and material to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal. 50 51.10 Not applicable
Information and material to support the sale of a drug to be used in the emergency treatment of a food-producing animal. 100 102.20 Not applicable
HUMAN DRUG ESTABLISHMENT LICENCE FEES Footnote 1
Good Manufacturing Practices Component:
  1. Fabrication
Basic Fee 17,402 18,107 Not applicable
Each Additional Category 4,361 4,538 Not applicable
Dosage Form Classes:
Two classes 8,708 9,061 Not applicable
Three classes 17,402 18,107 Not applicable
Four classes 21,762 22,642 Not applicable
Five classes 26,106 27,162 Not applicable
Six classes 30,454 31,686 Not applicable
Each additional class 1,748 1,819 Not applicable
Sterile dosage forms 8,708 9,061 Not applicable
  1. Packaging/Labelling
Basic Fee 11,636 12,107 Not applicable
Each Additional Category 2,907 3,026 Not applicable
Dosage Form Classes:
Two classes 5,803 6,039 Not applicable
Three or more classes 8,708 9,061 Not applicable
  1. Importation/Distribution
Basic Fee 7,256 7,551 Not applicable
Each Additional Category 1,816 1,891 Not applicable
Dosage Form Classes:
Two classes 3,630 3,778 Not applicable
Three or more classes 7,256 7,551 Not applicable
Each fabricator 1,748 1,819 Not applicable
Each additional dosage form class for each fabricator 881 917 Not applicable
  1. Distribution and Wholesaling
Distribution and Wholesaling Fee 4,361 4,538 Not applicable
  1. Testing
Testing Fee 2,907 3,026 Not applicable
Drug Analysis ComponentFootnote 2
Vaccines 29,001 30,174 Not applicable
Schedule D Drugs which are not vaccines or whole blood and its components 11,603 12,073 Not applicable
Drugs for human use that are prescription drugs, controlled drugs or narcotics 8,708 9,061 Not applicable
Drugs for human use, not included in any other item, for which a drug identification number has been assigned 4,361 4,538 Not applicable
Dealer's LicenceFootnote 3
Dealer's Licence 5,082 5,288 Not applicable
VETERINARY DRUG ESTABLISHMENT LICENCE FEES Footnote 1&Footnote 4
Good Manufacturing Practices Component
  1. Fabrication
Basic Fee 6,000 6,132 Not applicable
Each Additional Category 1,500 1,533 Not applicable
Dosage Form Classes:
Two classes 3,000 3,066 Not applicable
Three classes 6,000 6,132 Not applicable
Four classes 7,500 7,665 Not applicable
Five classes 9,000 9,198 Not applicable
Six classes 10,500 10,731 Not applicable
Each additional class 600 613.20 Not applicable
Sterile dosage forms 3,000 3,066 Not applicable
  1. Packaging/Labelling
Basic Fee 4,000 4,088 Not applicable
Each Additional Category 1,000 1,022 Not applicable
Dosage Form Classes:
Two classes 2,000 2,044 Not applicable
Three or more classes 3,000 3,066 Not applicable
  1. Importation/Distribution
Basic Fee 2,500 2,555 Not applicable
Each Additional Category 625 638.75 Not applicable
Dosage Form Classes:
Two classes 1,250 1277.50 Not applicable
Three or more classes 2,500 2,555 Not applicable
Each fabricator 600 613.20 Not applicable
Each additional dosage form class for each fabricator 300 306.60 Not applicable
  1. Distribution and Wholesaling
Distribution and Wholesaling Fee 1,500 1,533 Not applicable
  1. Testing
Testing Fee 1,000 1,022 Not applicable
Drug Analysis Component
Drug Identification Numbers for Veterinary Use 250 255.50 Not applicable
Dealer's LicenceFootnote 3
Dealer's Licence 1,750 1,788.50 Not applicable
MEDICAL DEVICE ESTABLISHMENT LICENCE FEE Footnote 1
Medical Devices Establishment Licence 8,109 8,438 Not applicable
PEST CONTROL PRODUCTS FEES AND CHARGES
Fees for application to register, or to amend the registration of, a Pest Control Product other than a semiochemical or Microbial Agent
Product Chemistry – active ingredient 4,873 5,071 Not applicable
Product Chemistry – end-use product or manufacturing concentrate 2,713 2,824 Not applicable
Toxicology data accompanying an application to register a pest control product that contains a new active ingredient 75,807 78,871 Not applicable
Toxicology data accompanying an application to register a pest control product –or to amend a pest control product –that contains an registered active ingredient 15,830 16,470 Not applicable
Toxicology data-acute toxicity studies 2,954 3,075 Not applicable
Exposure data accompanying an application to register a pest control that consists of or that contains a new active ingredient 17,498 18,205 Not applicable
Exposure data accompanying an application to register a pest control product –or to amend the registration of a pest control product –that contains a registered active ingredient, when a new risk assessment is necessary 5,758 5,992 Not applicable
Exposure data-other 5,214 5,426 Not applicable
Metabolism data 28,943 30,113 Not applicable
Residue data 15,838 16,479 Not applicable
Environment fate data accompanying an application to register a pest control product that consists of or that contains a new active ingredient 42,685 44,410 Not applicable
Environmental fate data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary 23,637 24,593 Not applicable
Environmental fate data-other 11,546 12,013 Not applicable
Environment toxicology data accompanying an application to register a pest control product that consists of or that contains a new active ingredient 37,277 38,784 Not applicable
Environmental toxicology data accompanying an application to register a pest control product ,or to amend the registration of a pest control product, that contains a registered active ingredient , when a new risk assessment is necessary 26,690 24,648 Not applicable
Environmental toxicology data-other 2,465 2,566 Not applicable
Value and effectiveness data for a pest control product 906 944 Not applicable
Identification of compensable data 2,162 2,251 Not applicable
Fees for application in respect of a Pest Control Product that is a semiochemical or Microbial Agent
Registration of a new active ingredient – food use 7,236 7,529 Not applicable
Registration of a new active ingredient – non-food use 4,341 4,517 Not applicable
Amendment of registration – new risk assessment necessary-environmental fate data, environmental toxicity data or exposure data 2,894 3,012 Not applicable
Amendment of registration – data required, label changes 1,447 1,506 Not applicable
Amendment of registration – data required, other 1,158 1,206 Not applicable
Amendment of registration – no data required 290 302 Not applicable
Registration of new active ingredient 579 603 Not applicable
Amendment of registration 290 302 Not applicable
Fees for other applications in respect of a Pest Control Product
Research authorization – major crops, other than research authorizations set out in paragraphs (c) and (d) 5,080 5,286 Not applicable
Research authorization – minor use crops, other than research authorizations set out in paragraphs (c) and (d) 5,080 5,286 Not applicable
Research authorization – microbial agents, semiochemicals and any substance listed in subparagraph 1(d) (ii) of these regulations. 1,217 1,267 Not applicable
Research authorization – greenhouse crops and non-agricultural uses 1,217 1,267 Not applicable
Research notifications 247 258 Not applicable
Registration of active ingredient to be used in pest control product manufactured only for export 7,827 8,144 Not applicable
Amendment to Registration of active ingredient to be used in pest control product manufactured only for export 1,133 1,180 Not applicable
Specification of maximum residue limit for a previously unexamined pest control product 125,461 130,531 Not applicable
Specification of maximum residue limit for an unregistered use of a previously examined pest control product 15,838 16,479 Not applicable
Applications not mentioned in Schedules
Processing 1,133 1,180 Not applicable
Applications not mentioned in schedules 247 258 Not applicable
Renewal 80 84 Not applicable
Annual Charge
Annual Charge 3,600 3,679 Not applicable
FEES CHARGED FOR FILING A CLAIM FOR EXEMPTION UNDER THE HAZARDOUS MATERIALS INFORMATION REVIEW ACT
Original Claim:
First 15 claims 1,800 1,839.60 Not applicable
Next ten claims 400 408.80 Not applicable
Over 25 claims 200 204.40 Not applicable
Refiled Claim:
First 15 claims 1,440 1,471.68 Not applicable
Next ten claims 320 327.04 Not applicable
Over 25 claims 160 163.52 Not applicable
Note: A 50% reduction for a small business that meets certain criteria is available. Please consult the Hazardous Materials Information Review Regulations for more information (section 4,5 and 7).
CANNABIS FEES Footnote 5
Licence Application Screening Fee:
Licence for micro-cultivation Not in effect 1,675 Not applicable
Licence for standard cultivation Not in effect 3,350 Not applicable
Licence for a nursery Not in effect 1,675 Not applicable
Licence for micro-processing Not in effect 1,675 Not applicable
Licence for standard processing Not in effect 3,350 Not applicable
Licence for sale for medical purposes Not in effect 3,350 Not applicable
Application for a security clearance Not in effect 1,691 Not applicable
Application for import or export permit Not in effect 624 Not applicable
Annual fee Not in effect See Cannabis Fees Order Not applicable
FEES SET BY MINISTERIAL AUTHORITY TO ENTER INTO CONTRACT
National Dosimetry Products and Services Fees See National Dosimetry Products and Services Fees See National Dosimetry Products and Services Fees Not applicable
Certificate of Pharmaceutical Product Fee 86 90 Not applicable
Drug Master File Fees:
New Master Files (file registration) 1,200 1,248 Not applicable
Drug Master Files - letter of access 170 176 Not applicable
Drug Master Files - Update 520 541 Not applicable
Footnote 1

Revised fees with respect to Drugs and Medical Devices were consulted on in 2017 and 2018. These new fees will be published on the Health Canada website in advance of implementation.

Return to footnote 1 referrer

Footnote 2

Product laboratory analysis activities based on the risks associated with various broad product types.

Return to footnote 2 referrer

Footnote 3

Fees for the examination of dealer's licence application.

Return to footnote 3 referrer

Footnote 4

If an establishment conducts licensable activities that include human and veterinary drugs, or controlled substances and / or narcotics, then the human drug fee supersedes the veterinary drug fee.

Return to footnote 4 referrer

Footnote 5

Cannabis Fees came into effect on October 17, 2018.

Return to footnote 5 referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: